Bristol-Myers Squibb (NYSE:BMY) reported positive top-line Phase 2 results for Reblozyl in alpha-thalassemia related anemia, covering both non-transfusion and transfusion-dependent patients. The ... Aqvesme is expected to be available in late January 2026.
The Food and Drug Administration (FDA) has approved Aqvesme™ (mitapivat) for the treatment of anemia in adults with alpha- or beta-thalassemia ... Seeking Alpha: Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript Yahoo Finance: Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia Seeking Alpha: U.S.
alpha thalassemia, FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia Nasdaq: FDA Approves Agios' AQVESME For Treatment Of Anemia In Alpha- And Beta-Thalassemia FDA Approves Agios' AQVESME For Treatment Of Anemia In Alpha- And Beta-Thalassemia
